Drug Class Description
Nucleoside reverse transcriptase inhibitors (NRTIs).

Generic Name
Didanosine

Drug Description
Gastro-resistant capsules.

Presentation
Capsules, didanosine 125mg , 200mg , 250mg , 400mg .

Indications
As part of a combination therapy for antiviral treatment of HIV infected patients.

Adult Dosage
Under 60kg, initially 250mg daily in one or two divided doses60kg or over, initially 400mg daily in one or two divided doses 12 hours apart.Videx EC should be administered at least two hours after a meal.

Child Dosage
Under 6 years, not recommended; over 6 years, initially 240 mg/m2 daily (or 180 mg/m2 daily in combination with zidovudine) in one or two divided doses 12 hours apart.

Contra Indications
Hypersensitivity to didanosine or to any of the excipients. Children younger than six years. Children younger than six years.

Special Precautions
Renal or hepatic impairment. Pancreatitis; monitor serum amylase levels before and during therapy. Monitor uric acid, triglyceride and liver enzymes. Check for peripheral neuropathy. Phenylketonuria. Monitor retinal changes in children. Lactic acidosis. Pregnancy, lactation.

Interactions
Co-administration with drugs known to cause peripheral neuropathy or pancreatitis may increase the risk of these toxicities. Ganciclovir.

Adverse Reactions
Pancreatitis, peripheral neuropathy. Abnormal liver function tests; rarely liver failure. Diarrhoea, nausea/ vomiting, allergic reactions, diabetes mellitus, dry mouth, elevated uric acid levels. Rarely retinal or optic nerve changes. Blood dyscrasias. Lactic acidosis.

Manufacturer
Bristol-Myers Squibb

Drug Availability
(POM)

Updated
26 March 2009